Cervical Cancer Treatment Market Size, Share Report 2026

Summary
Table Of Content

Market Insights

The cervical cancer treatment market will be highlighting excellent growth at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2018 to 2026. Cervical cancer occurs in women in an age group ranging from 14 to 49 years. The human papillomavirus (HPV) is the main causative agent for the occurrence of cervical cancer, which is sexually transmitted. Cervical cancer can be avoided by performing an early screening test and immunizing against HPV infection with Gardasil.

It is quite obvious that the generic market has the major economic share in the cervical cancer treatment market; however, the advent of biologics in the form of monoclonal antibodies and biosimilars has resulted in a major paradigm shift in the treatment regimen. Z-100 and ADXS11-001 are currently in phase III clinical trials being tested for drug safety and efficacy in the treatment of cervical cancer.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Synopsis

Affordable reimbursement scenarios drive the chemotherapy market’s growth.

Chemotherapy is currently the dominant product segment in the cervical cancer treatment market. Drugs such as cisplatin, carboplatin, paclitaxel, doxorubicin, and gemcitabine are employed for the treatment of cervical cancer in advanced stages. Radiation therapy, such as external beam therapy and brachytherapy, is given concurrently with chemotherapy in some stages of cervical cancer to give an excellent synergistic effect. The side effects associated with both therapies are severe, thereby leading to the need for targeted drug therapy. Avastin (bevacizumab) and Keytruda (pembrolizumab), etc., are used in cancer immunotherapy, which possess impressive clinical efficacy, dose tolerance, and patient compliance. Targeted drug therapy will be the fastest-growing market during the forecast period owing to the strong drug pipeline in phase III clinical trials, such as nimotuzumab and atezolizumab. Cervical hysterectomy involves the removal of the uterus, cervix, and sometimes the fallopian tubes in women suffering from early-stage cervical cancer.

The increasing number of patients screened for cervical cancer drives market growth in North America.

North America is the clear leader in the geographical segment of the cervical cancer treatment market. As per the latest research findings of the American Cancer Society, in 2019, approximately 13,170 new cases were diagnosed with cervical cancer, and around 4,250 women will die from cervical cancer. The rising prevalence of cervical cancer and increasing public health awareness resulting in early screening and medical intervention drive the market’s growth in North America. According to the facts presented by the World Health Organization (WHO), it is estimated that in the European region, 25,000 women will die from cervical cancer. The existence of major players such as Merck & Co., Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc., etc., propels the cervical cancer market’s growth in the European region. Asia Pacific will register outstanding growth during the forecast period owing to proactive government policies in early screening and medical intervention to curb the mortality related to cervical cancer and the presence of a huge generic market.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The market is segmented by product and geography.

Biopharmaceutical companies having a strong foothold in the cervical cancer treatment market are Allergan, Plc., Biocon Ltd., CooperSurgical, Inc., Eli Lilly & Company, F. Hoffmann-La-Roche AG, GlaxoSmithKline Plc., Ethicon, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Varian Medical Systems, Inc.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key questions are answered in this report.

What are the latest market trends prevailing in the cervical cancer treatment market?
Which biopharmaceutical companies are competing in the cervical cancer treatment market?
What are the clinical manifestations occurring in cervical cancer?
What are the screening tests performed and the treatment regimen adopted for the treatment of cervical cancer?
What led to the rise of targeted therapy, and how will it perform during the forecast period from 2018 to 2026?
What are the major attributes responsible for the dominance of North America in the cervical cancer treatment market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global CCT Market Portraiture
2.2. Global CCT Market, by Product, 2017 (US$ Mn)
2.3. Global CCT Market, by Geography, 2017 (US$ Mn)

Chapter 3. Cervical Cancer Treatment (CCT) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global CCT Market, by Key Players, 2017

Chapter 4. Global Cervical Cancer Treatment (CCT) Market, by Product
4.1. Overview
4.2. Chemotherapy
4.3. Targeted Therapy
4.4. Surgical Procedure
4.5. Radiation Therapy
4.6. Others
4.7. Pipeline Analysis
4.7.1. Phase III Drugs
4.7.1.1. Z-100
4.7.1.2. ADXS11-001
4.7.1.3. Nimotuzumab
4.7.1.4. Atezolizumab
4.7.2. Tabular Representation of Drug Pipeline in Phase II and I

Chapter 5. Global Cervical Cancer Treatment (CCT) Market, by Geography
5.1. Overview
5.2. North America CCT Market Analysis, 2016 – 2026
5.2.1. North America CCT Market, by Product, 2016 – 2026 (US$ Mn)
5.2.2. North America CCT Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe CCT Market Analysis, 2016 – 2026
5.3.1. Europe CCT Market, by Product, 2016 – 2026 (US$ Mn)
5.3.2. Europe CCT Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific CCT Market Analysis, 2016 – 2026
5.4.1. Asia Pacific CCT Market, by Product, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific CCT Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America CCT Market Analysis, 2016 – 2026
5.5.1. Latin America CCT Market, by Product, 2016 – 2026 (US$ Mn)
5.5.2. Latin America CCT Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East and Africa CCT Market Analysis, 2016 – 2026
5.6.1. MEA CCT Market, by Product, 2016 – 2026 (US$ Mn)
5.6.2. MEA CCT Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Allergan, Plc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Biocon Ltd.
6.3. CooperSurgical, Inc.
6.4. Eli Lilly & Company
6.5. F.Hoffman La-Roche AG
6.6. GlaxoSmithKline, Plc.
6.7. Ethicon, Inc.
6.8. Merck & Co., Inc.
6.9. Teva Pharmaceutical Industries Ltd.
6.10. Varian Medical Systems, Inc.

List of Figures

FIG. 1 Cervical Cancer Treatment (CCT) Market: Research Methodology
FIG. 2 CCT Market Segmentation
FIG. 3 Global CCT Market, by Product, 2017 (US$ Mn)
FIG. 4 Global CCT Market, by Geography, 2017 (US$ Mn)
FIG. 5 Attractive Investment Proposition: by Geography, 2017
FIG. 6 Competitive Analysis: Global CCT Market, by Key Players, 2017
FIG. 7 Global Chemotherapy Market for Cervical Cancer Treatment, 2016 – 2026 (US$ Mn)
FIG. 8 Global Targeted Therapy Market for CCT, 2016 – 2026 (US$ Mn)
FIG. 9 Global Surgical Procedure Market for CCT, 2016 – 2026 (US$ Mn)
FIG. 10 Global Radiation Therapy Market for CCT, 2016 – 2026 (US$ Mn)
FIG. 11 Global Other Products Market for CCT, 2016 – 2026 (US$ Mn)
FIG. 12 U.S. CCT Market, 2016 – 2026 (US$ Mn)
FIG. 13 Canada CCT Market, 2016 – 2026 (US$ Mn)
FIG. 14 U.K. CCT Market, 2016 – 2026 (US$ Mn)
FIG. 15 Germany CCT Market, 2016 – 2026 (US$ Mn)
FIG. 16 Rest of Europe CCT Market, 2016 – 2026 (US$ Mn)
FIG. 17 China CCT Market, 2016 – 2026 (US$ Mn)
FIG. 18 Japan CCT Market, 2016 – 2026 (US$ Mn)
FIG. 19 Rest of Asia Pacific CCT Market, 2016 – 2026 (US$ Mn)
FIG. 20 Brazil CCT Market, 2016 – 2026 (US$ Mn)
FIG. 21 Mexico CCT Market, 2016 – 2026 (US$ Mn)
FIG. 22 Rest of Latin America CCT Market, 2016 – 2026 (US$ Mn)
FIG. 23 GCC CCT Market, 2016 – 2026 (US$ Mn)
FIG. 24 Rest of MEA CCT Market, 2016 – 2026 (US$ Mn)

List of Tables

TABLE 1 Global Cervical Cancer Treatment (CCT) Market Portraiture
TABLE 2 Global CCT Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 3 Global CCT Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 4 North America CCT Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 5 North America CCT Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 6 Europe CCT Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 7 Europe CCT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 8 Asia Pacific CCT Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 9 Asia Pacific CCT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 10 Latin America CCT Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 11 Latin America CCT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 Middle East and Africa CCT Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 13 Middle East and Africa CCT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 14 Allergan, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 15 Biocon Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 CooperSurgical, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 Eli Lilly & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 F.Hoffman La-Roche AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 GlaxoSmithkline, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 Ethicon, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Teva Pharmaceuticals Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Varian Medical Systems, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Frequently Asked Questions

What is the size of Cervical Cancer Treatment Market?

The market for Cervical Cancer Treatment Market is expected to reach XX Mn by 2026.

What is the Cervical Cancer Treatment Market CAGR?

The Cervical Cancer Treatment Market is expected to see significant CAGR growth over the coming years, at 5.2%.

What is the Forecast period considered for Cervical Cancer Treatment Market?

The report is forecasted from 2018-2026.

What is the base year considered for Cervical Cancer Treatment Market?

The base year of this report is 2017.

Who are the major players in this market?

Eli Lilly & Company, F. Hoffmann-La-Roche AG, GlaxoSmithKline Plc., Ethicon, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd are some of the major players in the global market.

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$7699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –